Our proprietary PETization platform enables the rapid translation of therapeutic monoclonal antibodies (mAbs) between species.
Our mAbs are uniquely designed to be accepted by a patient's immune system as "native," a property we refer to as "100% species-specificity."
Our most advanced therapies in development are focused on treatments within four general areas: chronic pain, chronic inflammation, allergy, and immuno-oncology (cancer).
We believe biologic therapies as a class offer significant advantages over current treatments in these areas, including: safety, longer duration of action (and therefore less frequent dosing), and injectability.
Our team of scientists and veterinarians are working to investigate further opportunities for new biologic therapies.
7-9 March 2016
Cowen Annual Health Care Conference, Boston, MA, U.S.
10-12 May 2016
Bank of America Merrill Lynch 2016 Health Care Conference, Las Vegas, U.S.
8–11 June 2016
American College of Veterinary Internal Medicine Forum, CO, U.S.
22-25 June 2016
FECAVA Eurocongress, Vienna, Austria
27–30 July 2016
Veterinary Pain Short Course, San Diego, CA, U.S.
17–19 August 2016
International Veterinary Immunology Symposium, Gold Coast, Australia
26-30 September 2016
World Congress on Pain, Yokohama, Japan
Unit 5, Sragh Technology Park
Rahan Road, Tullamore
Co. Offaly, R35 FR98
P: + 353 5793 24522
Level 8, 31 Queen Street
P: +61 (3) 9610 4400
275 Post Street
San Francisco, CA 94108